Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

Ahead of the Clinical Trials at the Summit (CTS) meeting in Las Vegas, Nevada, Victor Gonzalez, MD, shared an overview of his presentation. Dr. Gonzalez is a trial investigator in the REMAIN follow-up ...

Lineage Cell Therapeutics will be presenting data on the safety and tolerability of RG6501 (OpRegen) for the treatment of geographic atrophy, secondary to age-related macular degeneration during the ...

The European Commission (EC) granted marketing authorization for Afqlir (aflibercept), which is a 2 mg vial kit and pre-filled syringe for intravitreal injection. This is a biosimilar to reference ...

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing tinlarebant's potential to treat geographic atrophy.